Beyond fibrinolysis: The role of plasminogen activator inhibitor-1 and vitronectin in vascular wound healing

被引:27
|
作者
Stefansson, S
Haudenschild, CC
Lawrence, DA
机构
[1] Amer Red Cross, Jerome H Holland Lab, Dept Biochem, Rockville, MD 20855 USA
[2] Amer Red Cross, Jerome H Holland Lab, Dept Pathol, Rockville, MD 20855 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1016/S1050-1738(98)00003-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Plasminogen activator inhibitor-1 (PAI-1), as the name implies, is the primary in vivo inhibitor of both tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). PAI-1 also binds to other nonproteinase ligands, including the matrix protein vitronectin, glycosaminoglycans such as heparin, and the endocytic clearance receptor, the low-density-lipoprotein-receptor-related protein (LRP). PAI-1 belongs to the superfamily of serine proteinase inhibitors (serpins), and, like other serpins, it acts as "suicide inhibitor" that reacts only one with a target proteinase. The suicide mechanism results in irreversible modification of the serpin and an extensive change in its conformation. In the case of PAI-1, this conformational change is important not only for inhibition of the proteinase, but it also causes changes in affinity for vitronectin and LRP. These changes have important consequences for cell migration. (C) 1998, Elsevier Science Inc.
引用
收藏
页码:175 / 180
页数:6
相关论文
共 50 条
  • [1] Plasminogen activator inhibitor-1 regulates the vascular expression of vitronectin
    Luo, M.
    Ji, Y.
    Luo, Y.
    Li, R.
    Fay, W. P.
    Wu, J.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2017, 15 (12) : 2451 - 2460
  • [2] Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice
    Eitzman, DT
    Westrick, RJ
    Nabel, EG
    Ginsburg, D
    [J]. BLOOD, 2000, 95 (02) : 577 - 580
  • [3] Role of increased plasminogen activator inhibitor-1 and vitronectin in gestational diabetes mellitus
    Ozgen, Levent
    Ozgen, Gulten
    Dincgez, Burcu
    Bayram, Feyza
    [J]. REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2023, 69 (09):
  • [4] Role of plasminogen activator inhibitor-1 and vitronectin in the response to arterial injury in mice
    Konstantinides, S
    Schafer, K
    Thinnes, T
    Loskutoff, DJ
    [J]. CIRCULATION, 1999, 100 (18) : 703 - 703
  • [5] Fibrinolysis and diabetic vascular disease: roles of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor
    Aso, Yoshimasa
    [J]. FUTURE LIPIDOLOGY, 2006, 1 (04): : 429 - 440
  • [6] Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1
    Skurk, T
    Hauner, H
    [J]. INTERNATIONAL JOURNAL OF OBESITY, 2004, 28 (11) : 1357 - 1364
  • [7] Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1
    T Skurk
    H Hauner
    [J]. International Journal of Obesity, 2004, 28 : 1357 - 1364
  • [8] Emodin upregulates urokinase plasminogen activator, plasminogen activator inhibitor-1 and promotes wound healing in, human fibroblasts
    Radha, K. S.
    Madhyastha, H. K.
    Nakajima, Y.
    Omura, S.
    Maruyama, M.
    [J]. VASCULAR PHARMACOLOGY, 2008, 48 (4-6) : 184 - 190
  • [9] Comment on "Role of increased plasminogen activator inhibitor-1 and vitronectin in gestational diabetes mellitus"
    Yin, Hejia
    Shi, Rou
    [J]. REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2024, 70 (04):
  • [10] Plasminogen activator inhibitor-1 in vascular thrombosis
    Westrick, Randal J.
    Eitzman, Daniel T.
    [J]. CURRENT DRUG TARGETS, 2007, 8 (09) : 996 - 1002